Welcome to our dedicated page for Bon Natural Life news (Ticker: BON), a resource for investors and traders seeking the latest updates and insights on Bon Natural Life stock.
Bon Natural Life Limited (NASDAQ: BON) is a Cayman Islands company active in the natural, health, and personal care industries, with operations centered in Xi’an, China. Company news frequently describes Bon as a bio-ingredient solution provider focused on functional active ingredients extracted from natural herb plants, fragrance compounds, health supplements, and bioactive food ingredients.
The BON news feed highlights developments across several product and technology areas. Investors and analysts can follow announcements on fragrance compounds such as ambroxide and related natural fragrance ingredients, including distribution agreements targeting the Asia-Pacific and industrial fabric fragrance markets. News also covers health supplement (powder drink) launches and cooperation agreements for natural prebiotic series and “prebiotic + postbiotic” gut health products centered on super prebiotic stachyose.
Another recurring theme in BON’s news is its work with tea pigment-based digestive health products and kombucha-inspired beverages. The company reports on strategic sales agreements in Greater China for second-generation tea pigment digestive health products and high-tea-pigment beverages produced through controlled fermentation using SCOBY cultures. These updates provide insight into Bon’s positioning in digestive wellness and functional beverage segments.
Bon Natural Life also issues news about its Apple Series metabolic health products based on apple polyphenols and plant proteins, as well as about its AI-powered new drug R&D platform that screens natural and TCM-derived compounds for weight management and other therapeutic potential. Regulatory and corporate governance items, such as Nasdaq compliance notifications and senior management changes, are disclosed through press releases and corresponding Form 6-K filings.
By reviewing BON news on this page, users can track product pipeline updates, distribution partnerships, AI-driven research milestones, and listing status disclosures that shape the company’s business trajectory.
Bon Natural Life (Nasdaq: BON), a bio-ingredient solution provider in the natural, health and personal care industry, has successfully regained compliance with Nasdaq's continued listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel on July 2, 2025, verifying that BON has met the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2).
Following BON's compliance plan submission on May 16, 2025, and a hearing presentation on June 5, 2025, the Panel granted the company's request to maintain its Nasdaq Capital Market listing. BON will remain under a Discretionary Panel Monitor for one year to ensure ongoing compliance with listing standards.
Bon Natural Life (Nasdaq: BON) has secured a significant $16 million non-exclusive distribution agreement with Beijing Huahai Keyuan Technology for its natural prebiotic product series in China. The 24-month agreement focuses on marketing and distributing BON's advanced gut health products featuring a "Prebiotic + Postbiotic" complex with super prebiotic stachyose as the flagship ingredient.
The partnership leverages Huahai Keyuan's strong market presence and commercialization expertise in China's wellness sector. BON's innovative formulation aims to provide rapid and sustained support for gut microbiota, potentially redefining the gut health market while driving growth and shareholder value.
Bon Natural Life Limited (BON) has announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade for marketing and distributing BON's tea pigment series health products in China. The agreement spans 24 months with a total contract value of $24 million.
The company's tea pigments, which offer benefits in lipid modulation, glycemic control, antioxidant activity, and anti-peptic ulcer properties, are targeting the digestive wellness and blood glucose regulation markets. With strong market fundamentals and global tea popularity, the venture has potential to reach a $1 billion market valuation.
Bon Natural Life Limited (BON) has announced an exclusive cooperation agreement with Beijing Huahai Keyuan for the distribution of its postbiotic hypoglycemic ingredients. The agreement spans 36 months with a contract value of $32 million. BON's patented product is designed to regulate blood sugar and control post-meal glucose spikes, offering advantages in safety and convenience.
The company is targeting the postprandial blood glucose control market, which has a size of over $30 billion and maintains a 7.5% compound annual growth rate. BON expects significant market advancement and growth in sales and profits over the next 2-3 years through this product line.
Bon Natural Life Limited (BON) has announced a 1-for-25 reverse stock split effective May 19, 2025, at 12:01 a.m. Eastern Time. The reverse split is primarily aimed at maintaining Nasdaq listing compliance by meeting the $1.00 minimum bid price requirement. Following the split, each 25 existing Class A ordinary shares will be consolidated into one new share, with fractional shares rounded up.
The company will maintain its "BON" trading symbol on Nasdaq with a new CUSIP number G14492204. Additionally, BON's authorized share capital will increase to 1 billion Class A ordinary shares, 50 million Class B shares, and 50 million preference shares. The Class B shares' conversion ratio to Class A shares will change from 1:1 to 1:25.
BON Natural Life Limited (Nasdaq: BON) has announced the launch of its innovative sleep health product series, featuring a patent-pending "Glucoraphanin-Myrosinase" delivery system. This breakthrough technology aims to enhance the bio-availability of glucoraphanin, a key compound found in broccoli that converts to sulforaphane in the body.
The company's proprietary system addresses the inefficient enzymatic conversion of glucoraphanin to sulforaphane, which typically limits the body's ability to access broccoli's full health benefits. Sulforaphane is associated with multiple health advantages, including sleep regulation, anti-cancer properties, and neuro-protective effects.
CEO Yongwei Hu emphasizes that BON's new sleep health products are designed to outperform traditional formulations through superior bio-availability and enhanced biological potency, positioning the company to capitalize on market opportunities in the sleep health sector.
Bon Natural Life (BON) has secured a significant $12 million 24-month supply agreement with Shanghai Yunsheng to co-develop apple polyphenol-infused health solutions. The partnership focuses on combining BON's patented extraction technology for antioxidant-rich apple polyphenols with plant-based proteins.
The initiative targets multiple health benefits including weight management, metabolic health, lipid management, and reduction of age-related muscle atrophy. Market validation shows similar apple polyphenol blends generating $40 million in recurring revenue, with monthly sales exceeding 500,000 units.
BON aims to capitalize on this high-growth market through dual revenue streams: standalone nutraceuticals and functional food additives, while maintaining strong profit margins.